A European multi-center, randomized controlled trial of Pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation
Pirfenidone did not show superiority over placebo and standard care in this exploratory trial. It cannot be recommended for treating BOS. Further research is needed to explore other treatments for CLAD to improve long-term outcomes after lung transplantation.
Authors
- Jens Gottlieb (ORCID: https://orcid.org/0000-0002-9540-9022)
- Erik A.M. Verschuuren (ORCID: https://orcid.org/0000-0002-6807-6744)
- Jim Lordan
- Robin Vos (ORCID: https://orcid.org/0000-0002-3468-9251)
- Nikolaus Kneidinger (ORCID: https://orcid.org/0000-0001-7583-0453)
- Michael Perch (ORCID: https://orcid.org/0000-0001-9740-1246)
- Geert M. Verleden (ORCID: https://orcid.org/0000-0003-3048-2429)
- Jesper Magnusson (ORCID: https://orcid.org/0000-0002-5630-0155)
- Inga Leuckfeld
- Paul Corris
- Vasiliki Bessa
Institutions
- University of Copenhagen (DK)
- Oslo University Hospital (NO)
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Universitair Ziekenhuis Leuven (BE)
- Sahlgrenska University Hospital (SE)
- Freeman Hospital (GB)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Medizinische Hochschule Hannover (DE)
- Ruhrlandklinik (DE)
- Newcastle upon Tyne Hospital (GB)
- German Center for Lung Research (DE)
- West German Heart and Vascular Center Essen (DE)
- Ludwig-Maximilians-Universität München (DE)
- Newcastle University (GB)
Publication Details
- Journal
- European Respiratory Journal
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1183/13993003.02154-2024
- Citations
- 1
- Primary Topic
- Transplantation: Methods and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.01